PEMBROLIZUMAB, PEMETREXED AND PLATINUM FOR THE FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER

Abstract

Pembrolizumab is the first programmed death protein 1 (PD-1) inhibitor, approved for the first line locally advanced or metastatic non-small cell lung cancer monotherapy, when tumor express high programmed death ligand 1 (PD-L1) level (≥50 proc.), with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. It is currently approved that pembrolizumab together with pemetrexed and platinum significantly prolonged overall survival and progression–free survival rates compared with chemotherapy only regardless of PD-L1 expression for the metastatic non-small non-squamous cell lung cancer. This treatment regimen is safe and tolerable. This is a standard of modern treatment of metastatic non-small non-squamous cell lung cancer.